Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 Est.

Benzinga Newsdesk www.benzinga.com Positive 92.8%

Neg 0% Neu 0% Pos 92.8%

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 analyst estimate..